AML Treatment: Individualized Approaches for Unfit Patients
Hear’s a breakdown of the key takeaways from the provided text, focusing on the treatment of acute myeloid leukemia (AML):
* ASCT After Venetoclax + HMA: allogeneic stem cell transplantation (ASCT) is important for long-term survival in AML patients. Treatment with venetoclax plus hypomethylating agents (HMA) can improve a patient’s condition enough to become eligible for ASCT. A Mayo Clinic study showed a 3-year survival rate of 62% for patients who received a transplant after responding to venetoclax + HMA.
* Venetoclax + HMA is Not Curative: The authors emphasize that venetoclax + HMA therapy is generally not a cure on its own.
* Individualized Treatment & NGS Testing: A personalized approach to treatment is recommended. Comprehensive Next-Generation Sequencing (NGS) testing (or at least testing for actionable mutations) is advised to help select the most appropriate therapies, and results should be available quickly.
* Key Statistics & Further Reading: The text references statistics from the American Cancer Society and cites research articles in Blood Cancer Journal and journal of Clinical Oncology. It also mentions FDA approval of venetoclax in combination for AML.
In essence, the text advocates for a strategy of using venetoclax + HMA to get patients into a condition where they can benefit from the potentially curative ASCT, guided by genetic testing to personalize treatment.